Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Open-label Phase I Dose Escalation Study of Dinutuximab Beta in Combination With Vincristine/Doxorubicin/Cyclophosphamide and Ifosfamide/Etoposide in Pediatric, Adolescent, and Adult Patients With GD2-positive Ewing Sarcoma

NCT06839703 is registered in ClinicalTrials.gov with Prof. Dr. Dirk Reinhardt as lead sponsor.

NCT NCT06839703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Open-label Phase I Dose Escalation Study of Dinutuximab Beta in Combination With Vincristine/Doxorubicin/Cyclophosphamide and Ifosfamide/Etoposide in Pediatric, Adolescent, and Adult Patients With GD2-positive Ewing Sarcoma
Lead sponsor
Prof. Dr. Dirk Reinhardt
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 1, 2025
Completion date
March 1, 2027
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk gd2-positive ewing sarcoma